Immuron Limited (ASX:IMC)
Australia · Delayed Price · Currency is AUD 0.0420
+0.0050 (13.51%)
Aug 26, 2026, 3:02 PM AEST
Immuron Revenue
Immuron had revenue of 4.18M AUD in the half year ending December 31, 2025, with 77.64% growth. This brings the company's revenue in the last twelve months to 7.48M, up 14.30% year-over-year. In the fiscal year ending June 30, 2025, Immuron had annual revenue of 7.29M with 48.63% growth.
Revenue (ttm)
7.48M
Revenue Growth
+14.30%
P/S Ratio
1.62
Revenue / Employee
1.07M
Employees
7
Market Cap
12.09M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 7.29M | 2.38M | 48.63% |
| Jun 30, 2024 | 4.90M | 3.10M | 171.67% |
| Jun 30, 2023 | 1.80M | 1.04M | 135.85% |
| Jun 30, 2022 | 765.19K | 619.42K | 424.91% |
| Jun 30, 2021 | 145.78K | -2.85M | -95.13% |
| Jun 30, 2020 | 2.99M | 604.81K | 25.33% |
| Jun 30, 2019 | 2.39M | 544.52K | 29.55% |
| Jun 30, 2018 | 1.84M | 446.71K | 31.99% |
| Jun 30, 2017 | 1.40M | 395.12K | 39.47% |
| Jun 30, 2016 | 1.00M | -1.30K | -0.13% |
| Jun 30, 2015 | 1.00M | 21.33K | 2.17% |
| Jun 30, 2014 | 981.05K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| EZZ Life Science Holdings | 61.40M |
| Neurotech International | 7.07M |
| Cambium Bio | 668.79K |
| AdAlta | 478.23K |
| Bio-Gene Technology | 390.63K |
| ReNerve | 333.21K |
| Invex Therapeutics | 229.08K |
| Patrys | 100.38K |
Immuron News
- 5 weeks ago - Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year - GlobeNewsWire
- 7 weeks ago - Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy - GlobeNewsWire
- 4 months ago - Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00 - Accesswire
- 4 months ago - Immuron Double Digit 3Q Sales Growth - GlobeNewsWire
- 6 months ago - Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target - Accesswire
- 6 months ago - Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference - Benzinga
- 7 months ago - Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target - Accesswire
- 7 months ago - Immuron Reports Continued Sales Growth - GlobeNewsWire